New hope for Hard-to-Treat cancers: BB-1709 enters human trials
Disease control
Recruiting now
This early-phase study tests a new drug called BB-1709 in 300 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also look at how the drug moves through the body …
Phase: PHASE1 • Sponsor: Bliss Biopharmaceutical (Hangzhou) Co., Ltd • Aim: Disease control
Last updated May 13, 2026 16:01 UTC